FDA Admits It Has Yet To Fill In Big Gaps On Biosimilar Regs
The U.S. Food and Drug Administration sketched new details Wednesday on how biosimilar medicines can win approval, but said it's yet to decide some of the industry's biggest questions, including how...To view the full article, register now.
Already a subscriber? Click here to view full article